39,140 Shares in Novanta Inc. $NOVT Acquired by Summit Creek Advisors LLC
Summit Creek Advisors LLC has acquired 39,140 shares of Novanta Inc. (NASDAQ:NOVT) worth approximately $6.35 million, making it their 19th largest position. Other institutional investors have also adjusted their stakes in Novanta, while CEO Matthijs Glastra recently sold 6,500 shares. Novanta reported strong quarterly earnings, beating estimates, and analysts maintain a "Buy" consensus rating with an average target price of $194.00.
17,392 Shares in Novanta Inc. $NOVT Bought by Diversify Advisory Services LLC
Diversify Advisory Services LLC has acquired a new stake of 17,392 shares in Novanta Inc. (NASDAQ:NOVT) during the second quarter, valued at approximately $2.45 million. Other institutional investors also increased their holdings in Novanta, which saw its stock trading down 6.9% at $157.11. The company reported strong Q2 earnings, beating analyst estimates, and has received updated "Strong Buy" and "Buy" ratings from several analysts, with an average target price of $194.00.
A Look at Novanta Inc (NOVT) After 6.9% Decline -- GF Value $154
Novanta Inc (NOVT) shares recently declined by 6.9% to $157.14, yet the stock remains 2.0% overvalued according to its GF Value™ of $154.02. Despite a strong GF Score™ of 87/100, indicating robust overall performance, the company's P/E ratio is higher than its historical median, and insiders have sold $11.5 million in shares over the past year with no buying activity. Investors are advised to consider these factors, including potential risks associated with its overvaluation and insider selling, before making investment decisions.
Federated Hermes SDG Engagement Equity Fund's Novanta Inc(NOVT) Holding History
Federated Hermes SDG Engagement Equity Fund holds 10,027.00 shares of Novanta Inc (NOVT), valued at $1.30 million, making up 1.49% of their portfolio. The initial purchase was in Q2 2026 at an average price of $129.49 per share. As of the current price of $166.57, the fund has an estimated gain of $371,801.16, representing a 28.64% return on this holding.
Oppenheimer Asset Management Inc. Buys New Stake in Novanta Inc. $NOVT
Oppenheimer Asset Management Inc. has acquired a new stake in Novanta Inc. (NASDAQ:NOVT), purchasing 35,729 shares valued at approximately $5.8 million, making institutional investors collectively own 98.35% of the company. Novanta recently exceeded quarterly earnings expectations with $0.89 EPS and $265.8 million in revenue, and has provided positive fiscal 2026 EPS guidance. Despite a CEO insider sale, analysts maintain a consensus "Hold" rating with a price target of $194.
T. Rowe Price (NOVT) discloses 6.2% beneficial stake in Novanta common stock
T. Rowe Price Associates, Inc. has disclosed a 6.2% beneficial ownership stake in Novanta Inc. (NOVN), amounting to 2,222,444 shares of common stock. The firm reported sole voting power over 2,216,715 shares and sole dispositive power over all 2,222,444 shares, while explicitly denying that the report constitutes an admission of beneficial ownership. This disclosure was made via a Schedule 13G SEC filing.
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Novanta (NOVT) is highlighted as a strong momentum pick due to its Zacks Momentum Style Score of B and Zacks Rank of #2 (Buy). The article details NOVT's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its promising outlook for investors.
Wasatch Advisors LP Has $123.30 Million Stock Position in Novanta Inc. $NOVT
Wasatch Advisors LP reduced its holdings in Novanta Inc. by 23.7% in the second quarter, now owning 759,992 shares valued at $123.3 million. Despite this, institutional investors collectively hold 98.35% of Novanta's stock. The company recently exceeded earnings estimates, reporting $0.89 per share on revenue of $265.81 million, though analyst sentiment remains cautious with a "Hold" consensus rating and a $194.00 price target.
Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 18.3% in the first quarter, now owning 456,241 shares valued at $53.9 million. Novanta exceeded quarterly earnings expectations with $0.89 EPS and $265.81 million in revenue, and analysts currently hold a consensus "Hold" rating with a $194 price target. CEO Matthijs Glastra also sold 6,500 shares under a pre-arranged trading plan.
Avoiding Lag: Real-Time Signals in (NOVT) Movement
This article analyzes Novanta Inc. (NASDAQ: NOVT) using AI-generated real-time signals, indicating a strong overweight bias across all time horizons. It highlights an exceptional risk-reward short setup and provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels to help traders navigate NOVT's movement.
Why Novanta (NOVT) Is Up 16.7% After Q2 Results And Its Largest Medical Acquisition
Novanta Inc. (NOVT) reported strong Q2 2026 results, with sales of US$265.81 million and net income of US$12.54 million, leading to a 16.7% stock increase. The company's largest acquisition to date, Riverpoint Medical, significantly expands its medical market presence and recurring consumables business. This deal, while raising integration risks, supports Novanta's acquisition-led growth strategy, with updated 2026 revenue guidance now including Riverpoint's contribution.
Novanta (NASDAQ:NOVT) Raised to Buy at Wall Street Zen
Wall Street Zen upgraded Novanta (NASDAQ:NOVT) from "hold" to "buy" after the company exceeded quarterly expectations, reporting $0.89 EPS and $265.81 million in revenue. Despite this, the broader analyst consensus remains "Hold" with an average price target of $194.00. The stock opened at $166.37, with a market capitalization of $6.29 billion, and institutional investors own 98.35% of the company.
ETFs Investing in Novanta Inc Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Novanta Inc. (NOVT) stocks. The list is sorted by market value and includes various details for each ETF such as issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different market segments like mid-cap, small-cap, total market, and thematic investments in technology and robotics.
California State Teachers Retirement System Purchases 7,506 Shares of Novanta Inc. $NOVT
The California State Teachers Retirement System increased its stake in Novanta Inc. (NASDAQ:NOVT) by 22% during the first quarter, purchasing 7,506 additional shares to bring its total holdings to 41,627 shares valued at $4.9 million. This increase occurred despite Novanta's CEO selling a substantial number of shares and analysts maintaining a consensus "Hold" rating for the stock. The company reported strong second-quarter earnings and revenue, exceeding analyst estimates, and provided an upbeat outlook for the rest of the year.
Novanta Delivers Double‑Digit Growth and Margin Expansion in Second Quarter 2026
Novanta (NOVT) reported a strong second quarter of 2026, with GAAP revenue up 10% to $266 million and organic growth of 9.3%. The company saw significant profitability improvements, including a 16% increase in adjusted EBITDA to $60.7 million and a 17% rise in adjusted diluted EPS to $0.89. Analysts currently rate NOVT with a Buy, while TipRanks' AI Analyst, Spark, has a Neutral rating, noting strong fundamentals but expensive valuation and weaker near-term technicals.
NOVANTA INC 3Q 2026: Revenue $265.8M, EPS $0.3— 10-Q Summary
NOVANTA INC (NOVT) reported strong third-quarter 2026 results, with revenue reaching $265.8 million, net income of $12.5 million, and diluted EPS of $0.30. These figures represent a significant increase compared to the previous year, driven by robust performance in its Automation and Medical segments. The company's growth was fueled by demand for robotics and advanced surgery offerings, along with strategic acquisitions and continued investments in manufacturing and systems.
Earnings Flash (NOVT) Novanta Inc. Posts Q2 Adjusted EPS $0.89 per Share, Vs. FactSet Est of $0.83
Novanta Inc. (NOVT) announced its second-quarter adjusted EPS of $0.89 per share, surpassing the FactSet estimate of $0.83 per share. This financial update indicates a stronger-than-expected performance for the quarter.
Novanta stock hits 52-week high at $171.99
Novanta Inc. (NOVT) has reached a new 52-week high of $172.31, reflecting a 34.62% return over the past year and a 28.68% gain year-to-date. Despite its strong performance, InvestingPro analysis indicates the stock is currently overvalued with a P/E ratio of 109.36 and a market cap of $6.31 billion. The company recently surpassed Q2 2026 earnings and revenue expectations, raising its outlook.
Is Novanta Inc (NOVT) Overvalued After Q2 Earnings Miss? GAAP EPS $0.30, Revenue $265.8M; GF Score: 87/100
Novanta Inc (NOVT) reported strong Q2 2026 financial results with GAAP revenue up 10.3% to $265.8 million and GAAP diluted EPS of $0.30, driven by operational execution and acquisitions. Despite a slight overvaluation according to GuruFocus' GF Value, the company shows robust financial strength and profitability. However, recent insider stock sales suggest potential caution for investors.
Novanta Q2 2026 earnings: Organic growth reaches 9.3% as margins expand
Novanta (Nasdaq: NOVT) reported strong Q2 2026 results with a 10.3% year-over-year revenue increase to $265.8 million and 9.3% organic growth, the highest since Q1 2023. GAAP diluted EPS rose significantly to $0.30, and adjusted EBITDA grew 16.4% to $60.7 million, with company-wide gross and adjusted EBITDA margins expanding. The company's Q3 and full-year guidance includes the Riverpoint Medical acquisition, which is expected to be immediately accretive and increase medical end-market exposure.
GUIDANCE: (NOVT) Novanta Inc. Expects Q3 Revenue Range $300.0M - $304.0M
Novanta Inc. (NOVT) has provided its revenue guidance for the third quarter, expecting it to be in the range of $300.0 million to $304.0 million. This financial outlook offers investors insight into the company's anticipated performance for the upcoming quarter.
Earnings Flash (NOVT) Novanta Inc. Posts Q2 Adjusted EPS $0.89 per Share, vs. FactSet Est of $0.83
Novanta Inc. (NOVT) reported Q2 adjusted EPS of $0.89 per share, surpassing FactSet's estimate of $0.83. This news comes as the company also announced rising Q2 adjusted earnings and revenue, leading to a lift in its 2026 guidance. Novanta also provided Q3 revenue and adjusted EPS guidance, along with news of its recent acquisition of Riverpoint Medical, LLC.
Novanta Announces Financial Results for the Second Quarter 2026
Novanta Inc. reported strong financial results for the second quarter of 2026, with GAAP revenue increasing 10% to $266 million and Adjusted EBITDA up 16% to $61 million. The company exceeded expectations in revenue, margins, and profitability, and also announced the acquisition of Riverpoint Medical, which is expected to significantly boost its medical consumables business and overall financial performance. Novanta provided optimistic financial guidance for the third quarter and full year 2026, incorporating the contributions from the recent acquisition.
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
Novanta (NOVT) reported strong Q2 earnings of $0.89 per share, surpassing the Zacks Consensus Estimate of $0.83, and revenues of $265.81 million, exceeding expectations by 1.64%. The company has consistently beaten EPS and revenue estimates over the past year. Despite its strong performance, Novanta currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market in the near future.
Novanta earnings in focus: Can bookings momentum drive growth?
Novanta Inc. is set to report its second-quarter results, with analysts expecting EPS of $0.86 and revenue of $262.3 million. Investors will be focused on whether the company can translate its strong first-quarter bookings momentum into sustained revenue growth and address margin performance concerns. The recent acquisition of Riverpoint Medical will also be a key discussion point regarding integration and enhanced growth in minimally invasive procedures.
ETFs Investing in Novanta Inc Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold stocks of Novanta Inc. The list is sorted by market value and includes various details such as issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs cover different market segments like mid-cap, small-cap, total market, and specific themes such as robotics and automation.
Novanta Inc Revenue Breakdown – BIVA:NOVT/N
Novanta Inc's latest financial data shows a total revenue of 17.68 B MXN. The Automation Enabling Technologies segment was the highest contributor at 9.03 B MXN, down from 10.23 B MXN the previous year. The United States remained the primary regional contributor, accounting for 9.36 B MXN.
Novanta Inc expected to post earnings of 83 cents a share - Earnings Preview
Novanta Inc is expected to announce earnings of 83 cents per share. This information is presented as an earnings preview by Refinitiv, available through TradingView News. The full article can be accessed on TradingView for those with unlimited access.
Novanta (NOVT) Reports Earnings Tomorrow: What To Expect
Novanta (NASDAQ: NOVT), a medicine and manufacturing technology provider, is set to report earnings tomorrow. The company beat revenue expectations last quarter, and analysts anticipate an 8.8% year-on-year revenue growth for the upcoming quarter. Despite some underperformance in the electronic components sector, analysts have largely reconfirmed their estimates for Novanta, with an average price target of $175.
Discipline and Rules-Based Execution in NOVT Response
This article provides an analysis of Novanta Inc. (NASDAQ: NOVT), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details specific institutional trading strategies, including long, breakout, and short positions, based on AI models and multi-timeframe signal analysis. The report identifies an exceptional risk-reward short setup and offers real-time signals and analysis for subscribers.
Novanta Completes Acquisition Of Riverpoint Medical
Novanta has acquired Riverpoint Medical from Arlington Capital Partners, a move expected to double Novanta's recurring medical consumables revenue to approximately $300 million and increase its medical end-market exposure to 60% of total revenue. The acquisition integrates Riverpoint's expertise in minimally invasive surgical consumables and IP-protected private-label products, unlocking a $2 billion incremental addressable market and enhancing Novanta's manufacturing footprint. This deal is projected to be immediately accretive to Novanta's organic growth, margins, and cash flows, with an estimated contribution of $0.18 to $0.25 adjusted earnings per share in 2027.
Discipline and Rules-Based Execution in NOVT Response
This article analyzes Novanta Inc. (NASDAQ: NOVT), highlighting a weak near and mid-term sentiment that could challenge its long-term positive outlook. AI models have generated three trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The analysis includes key risk-reward metrics and multi-timeframe signal analysis, indicating strong long-term support despite current weaknesses.
Novanta Inc (NOVT) Financial Health: Profitability & Balance Sheet Analysis
Novanta Inc (NOVT) has a robust financial status with a current score of 7.33, ranking 27th in its industry. The company reported a latest quarterly revenue of $257.71 million, showing a 10.43% year-over-year increase, and a net profit increase of 0.51% year-over-year. While its operating efficiency is average, key financial metrics like cash and cash equivalents, total assets, and free cash flow were not disclosed in detail.
Novanta (NOVT) Completes Riverpoint Medical Deal To Expand Recurring Consumables Revenue
Novanta (NOVT) has completed its acquisition of Riverpoint Medical, significantly increasing its exposure to the medical consumables market and expecting to approximately double its recurring medical consumables revenue. This deal marks a shift in Novanta's business mix towards a higher share of medical end-market exposure and adds a different revenue profile alongside its existing equipment and component lines. Investors should monitor how Novanta integrates Riverpoint Medical and reports on the recurring revenue from this acquisition.
NOVT|Novanta Inc|Price:137.890|Chg%:-3.730
Novanta Inc. (NOVT) is a supplier of core technology solutions for medical and advanced industrial original equipment manufacturers, with segments in Automation Enabling Technologies and Medical Solutions. The company's stock is currently priced at $137.770, with a market cap of $4.91 billion and a P/E TTM of 98.10. Key executives include CEO Matthijs Glastra and CFO Robert J. Buckley, and institutional shareholding has increased significantly.
Novanta Inc (NOVT) Institutional Confidence
Novanta Inc (NOVT) has an institutional shareholding score of 10.00, placing it first in the Electronic Equipment & Parts industry. The institutional shareholding proportion has increased by 22.19% quarter-over-quarter, now standing at 129.80%. Ron Baron is the largest institutional shareholder, holding 2.56% of shares outstanding.
Novanta completes Riverpoint Medical acquisition
Novanta Inc. announced the completion of its acquisition of Riverpoint Medical from Arlington Capital Partners. This acquisition significantly boosts Novanta's minimally invasive surgical consumables sector, doubling its recurring medical consumables revenue to approximately $300 million and increasing medical end-market exposure to
NOVT|Novanta Inc|Price:140.775|Chg%:-0.765
This article provides a comprehensive stock analysis of Novanta Inc (NOVT) from TradingKey, highlighting its strong fundamentals and significant growth potential. The company's valuation is considered fair, ranking 16th in its industry, with high institutional ownership and multiple "Strong Buy" ratings from analysts. Despite recent market performance, Novanta Inc's stock is expected to trend upwards in the medium term and is suitable for range-bound swing trading due to its current trading pattern.
Novanta completes acquisition of Riverpoint Medical By Investing.com
Novanta Inc. (NASDAQ: NOVT) has finalized its acquisition of Riverpoint Medical from Arlington Capital Partners. This acquisition is anticipated to boost Novanta's recurring medical consumables revenue, increase its medical end-market exposure, and contribute positively to its adjusted earnings per share and organic growth. Riverpoint Medical specializes in minimally invasive surgical consumables and will operate under Novanta's Medical Solutions segment.
Novanta completes acquisition of Riverpoint Medical
Novanta Inc. (NASDAQ:NOVT) has successfully acquired Riverpoint Medical from Arlington Capital Partners. This acquisition is expected to boost Novanta's recurring medical consumables revenue to approximately $300 million and increase its medical end-market exposure to 60% of total revenue. Novanta anticipates the acquisition will contribute between $0.18 and $0.25 of adjusted earnings per share in 2027 and be immediately accretive to its organic growth, adjusted gross margins, adjusted EBITDA growth, and cash flows.
Novanta Inc Revenue Breakdown – TRADEGATE:1GSN
Novanta Inc (1GSN) generated €834.90 million in revenue last year. Its top-performing segment, Automation Enabling Technologies, contributed €426.42 million, while the United States was the largest regional contributor with €441.89 million in revenue. The article provides a high-level overview of the company's financial performance by segment and geography.
Novanta Inc (NOVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Novanta Inc (NOVT), focusing on its support and resistance levels, various technical indicators, and moving averages. Currently, Novanta Inc's stock is trading between a resistance of $159.05 and a support of $131.73, indicating suitability for range-bound swing trading. The analysis includes a summary of indicator signals, such as MACD and RSI, and moving average signals, which collectively suggest a "Neutral" outlook for the stock.
Behavioral Patterns of NOVT and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Novanta Inc. (NASDAQ: NOVT), highlighting weak near and mid-term sentiment that could challenge a positive long-term outlook. It presents AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels. The report also notes a strong risk-reward short setup targeting a 12.7% downside.
Novanta (NOVT) Is Down 5.1% After Softer Sales And Earnings Momentum Raises Durability Questions
Novanta Inc. (NOVT) is experiencing a 5.1% dip after its sales and earnings momentum softened, sparking concerns about the durability of its business performance. The company's below-average sales growth over the last two years and lagging earnings growth compared to peers are raising questions about its high valuation, especially given its reliance on acquisitions for growth. Despite management reaffirming 2026 revenue guidance, investors are scrutinizing whether Novanta can achieve consistent earnings improvement and margin resilience.
Novanta (NOVT) Is Down 5.1% After Softer Sales And Earnings Momentum Raises Durability Questions
Novanta (NOVT) shares dropped 5.1% after concerns emerged regarding its softer sales and earnings momentum, raising questions about the durability of its business performance. The company's recent sales growth has been below average, and its earnings growth has lagged peers, despite reaffirming its 2026 revenue guidance. This has led to scrutiny over how much of Novanta's growth relies on acquisitions rather than organic demand.
Press Release: Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call
Novanta Inc. has announced it will release its second quarter 2026 financial results on Tuesday, August 2, 2026, after the market closes. The company will also host a conference call and live webcast at 5:00 p.m. ET on the same day to discuss these results. Details for accessing the webcast and replay will be available online.
NOVANTA INC TANGIBLE EQUITY UNIT(01/11/2028) To Go Ex-Dividend On July 31st, 2026 With 0.8125 USD Dividend Per Share
NOVANTA INC TANGIBLE EQUITY UNIT (01/11/2028) is scheduled to go ex-dividend on July 31st, 2026. The company will issue a dividend of 0.8125 USD per share. Investors should note this date for dividend eligibility.
Novanta Acquires Riverpoint Medical for Up to $1.45 Billion
Novanta Inc. (NASDAQ: NOVT) has signed a definitive agreement to acquire Riverpoint Medical from Arlington Capital Partners for an initial payment, with the potential for the total acquisition cost to reach up to $1.45 billion. Ropes & Gray advised Novanta on this transaction. The article indicates that full content access requires a standard 1-year membership.
Novanta announces Q2FY26 earnings release date
Novanta Inc. has scheduled the release of its second-quarter 2026 financial results for August 5, 2026, after the U.S. financial markets close. The company will then host a conference call on August 6, 2026, at 8:00 a.m. ET to discuss these results, with a webcast replay available until October 5, 2026, on its investor relations website. This announcement provides stakeholders with key dates for accessing the company's updated financial performance and related discussions.
Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call
Novanta Inc. (Nasdaq: NOVT) will release its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. The company will host a conference call the following day, Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. Interested parties can access the call via phone or a live webcast on the Investors section of Novanta's website, with a replay available until October 5, 2026.
